Glucan phosphate has been shown to enhance antimicrobial immunity in a variety of experimental models. However, the mechanisms by which glucans enhance resistance to infection remain largely unknown. Interferon-γ (IFN-γ) is a key regulator of both innate and acquired immunity. Suppression of IFN-γ production is a prominent feature of the altered immune response that follows major trauma or sepsis. The present studies were designed to determine the effect of glucan phosphate on IFN-γ expression in normal mice and endotoxin [lipopolysaccharide (LPS)]-tolerant mice. The model of LPS tolerance was used because it results in patterns of cytokine expression similar to those commonly observed following severe trauma or sepsis. Glucan treatment potentiated LPS-induced IFN-γ expression in control mice. The induction of LPS tolerance resulted in marked suppression of LPS-induced IFN-γ production. However, co-administration of glucan with LPS, during the tolerance induction phase, attenuated the LPS-tolerant response. Interleukin-12 (IL-12) and IL-18 are important mediators of LPS-induced IFN-γ production. LPS-induced IL-12 p40 mRNA expression was increased in the spleens of glucan-treated mice compared with controls. Induction of LPS tolerance caused marked suppression of IL-12 production, a response that was attenuated by glucan treatment. IL-18 was constitutively expressed in both control and LPS-tolerant mice, and LPS-induced serum levels of IL-18 were increased in mice treated with glucan. T cells isolated from glucan-treated mice exhibited increased IFN-γ expression in response to IL-12 and IL-18, as well as increased expression of the IL-12 and IL-18 receptors. The ability of glucan to potentiate IFN-γ expression in control mice provides a potential mechanism by which glucan enhances antimicrobial immunity. The ability of glucan to attenuate suppressed IFN-γ expression in LPS-tolerant mice denotes its potential benefit for the treatment of trauma and sepsis-induced immunosuppression.
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entation, and production of pro-inflammatory cytokines [1, 2] . Impairment of IFN-γ production is a hallmark of the altered immune function that follows sepsis and trauma [3, 4] . Some clinical trials have shown that administration of IFN-γ to trauma and high-risk surgical patients will improve immune function, increase resistance to infection and, in some cases, enhance survival [4] [5] [6] . Expression of IFN-γ is regulated, in part, by the macrophage-derived cytokines interleukin-12 (IL-12) and IL-18 [3, 7] . These two cytokines act synergistically to promote production of IFN-γ by T cells and NK cells. Suppression of IL-12 has been demonstrated in models of trauma and endotoxin [lipopolysaccharide (LPS)] tolerance [3, 8] . Administration of IL-12 to thermally injured mice will improve resistance to infection [8] . This effect appears to be mediated, in part, by enhancement of IFN-γ secretion. Therefore therapeutic strategies aimed at increasing IL-12 and IFN-γ expression may be beneficial in the treatment of the immunosuppression that results from trauma and sepsis. IL-18, initially termed IFN-γ-inducing factor, acts in combination with IL-12 to augment IFN-γ production, in addition to playing a role in the regulation of T cell differentiation. The effects of glucan treatment and LPS exposure on IFN-γ, IL-12 and IL-18 expression and function are not well understood. Glucans are β-1,3-linked glucose polymers that are intrinsic components of fungal cell walls and have broad immunomodulatory properties. Numerous investigators have shown that the phagocytic and intracellular antimicrobial functions of macrophages and neutrophils are enhanced following the administration of glucans in experimental and clinical models of infection [9, 10] . In experimental models, glucans have been shown to improve survival and increase microbial clearance in Gramnegative and Gram-positive bacteraemia, polymicrobial intra-abdominal sepsis, fungaemia and parasitaemia [9, 10] . Clinical studies have shown that glucans decrease antibiotic use, shorten stays in intensive care units, and improve infection-related survival in high-risk surgical and trauma patients [11] [12] [13] [14] . The mechanisms by which glucans modulate the immune response and stimulate antimicrobial immunity are not well understood. However, the hallmark of glucan-enhanced resistance to infection is the potentiation of macrophage-mediated antimicrobial function. Because IFN-γ is the most potent endogenous activator of macrophage function, we hypothesized that the glucan-induced enhancement of antimicrobial activity is mediated, in part, through its ability to potentiate IFN-γ secretion. The purpose of the present studies was to determine whether glucan phosphate would enhance the expression of IFN-γ in both immunocompetent and LPS-tolerant mice. Further studies were undertaken to better define the roles of IL-12 and IL-18 in the regulation of IFN-γ expression, and to assess the effects of glucan treatment on the expression and function of IL-12 and IL-18.
MATERIALS AND METHODS

Reagents
Glucan phosphate was generously provided by Dr David Williams (James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, U.S.A.). This glucan preparation was used because it has been well characterized and shown to be effective in enhancing resistance to infection in a variety of experimental models [15, 16] . Endotoxin levels in glucan phosphate were less than 1 endotoxin unit\mg, as determined by the Endospecy assay (Seigagaku, Tokyo, Japan 
Animal model
All studies were approved by the Institutional Animal Care and Use Committee at UTMB, and met NIH guidelines for the use of experimental animals in research. Female 6-8-week-old Balb\C mice (Harlan Sprague Dawley, Indianapolis, IN, U.S.A.) were used in all studies. Mice were housed in a monitored, light\dark-cycled environment and provided with standard lab chow and water ad libitum. Our experimental protocol is outlined in Table 1 . Specifically, LPS tolerance was induced by intraperitoneal injection of LPS daily for 2 days (0.4 mg:kg −" in 0.2 ml of normal saline). Control mice received normal saline (0.2 ml) in the same regimen. Additional mice in both groups also received glucan phosphate (40 mg\kg) simultaneously with saline or LPS. On day 4, all mice received a challenge dose of LPS (4 mg\kg, intraperitoneal). Sera and spleens were harvested at various time points after LPS challenge for assessment of cytokine expression. 
ELISA for murine cytokines
IFN-γ, IL-12 p70 and IL-18 in serum and conditioned medium were determined by ELISA. Briefly, standards or experimental samples were added to microplates coated with monoclonal antibody to the cytokine of interest and incubated for 2 h. After washing, horseradish peroxidase-conjugated, cytokine-specific antibody was added to each well, incubated for 2 h and washed. Substrate solution was added and incubated for 30 min, and the reaction was terminated by the addition of stop solution. Cytokine levels were determined by assessing absorbance at 450 nm using a microtitre plate reader (Dynatech Laboratories, Chantilly, VA, U.S.A.).
Reverse transcription-PCR (RT-PCR)
Total RNA was isolated from tissues using the TRI Reagent System (Molecular Research Center, Cincinnati, OH, U.S.A.) according to the manufacturer's protocol. A sample of 5 µg of total RNA was reverse-transcribed (42 mC for 50 min) using Superscript II reverse transcriptase (Gibco\BRL, Gaithersburg, MD, U.S.A.), oligo(dT) primers and dNTPs. The RT product (3-6 µl) was amplified using Taq DNA polymerase (1 unit\ reaction ; Sigma), dNTPs and product-specific primers. The PCR reaction was conducted for 35-40 cycles in a DNA thermal cycler (Barnstead\Thermolyne, Dubuque, IA, U.S.A.). β-Actin served as an internal control in all experiments. The following primers were used : β-actin, 5h-CTACAATGAGCTGCGTGTGG-3h (forward) and 5h-AAGGAAGGCTGGAAGAGTGC-3h (reverse) ; IFN-γ, 5h-AGCTCTGAGACAATGAACGC-3h (forward) and 5h-GGACAATCTCTTCCCCACCC-3h (reverse) ; IL-18 receptor α (IL-18Rα), 5h-TCTCGTC-TCTTTCCGCTATGCG-3h (forward) and 5h-TTAG-GACCAAAGTGTGAGAGAAGG-3h (reverse) ; IL-12 12 p40, 5h-TCTGCAGAGAAGGTCACACTG-3h (forward) and 5h-ACTTCGGTAGATGTTTCCTC-3h (reverse). The PCR products were separated on 2 % (w\v) agarose gels containing 1iTris\acetic acid\EDTA and ethidium bromide. Gels were visualized by UV illumination and photographed using a Fluor-S MultiImager (Bio-Rad, Hercules, CA, U.S.A.). The predicted sizes of the PCR products were 528 bp, 320 bp, 374 bp and 459 bp for β-actin, IFN-γ, IL-12 p40 and IL-18Rα respectively.
RNAse protection assay (RPA)
RPA was performed using the Riboquant system (Pharmingen, San Diego, CA, U.S.A.), as per the manufacturer's instructions. Briefly, radiolabelled RNA probes were synthesized from DNA template sets using T7 RNA polymerase, [α-$#P]UTP and pooled nonradiolabelled nucleotides. Isolated mRNA (10 µg of total RNA\sample) were hybridized with the purified riboprobes and then subjected to RNase digestion. DNA template sets included probes for the L32 and glyceraldehyde-3-phosphate dehydrogenase housekeeping genes that served as internal controls. Protected RNA species were separated on 5 % denaturing polyacrylamide gels using 0.5iTBE running buffer. Gels were run at 50 W constant power and then dried, and protected fragments were visualized using autoradiography.
Data analysis
For comparisons of numerical data from multiple groups, two-way ANOVA was performed followed by Tukey's test. A value of P 0.05 was considered statistically significant.
RESULTS
Glucan phosphate potentiates LPS-induced IFN-γ expression
We initially evaluated the ability of glucan phosphate to directly stimulate IFN-γ production in vivo. Our data showed that serum IFN-γ levels peaked at 6 h after intraperitoneal challenge with LPS ( Figure 1A ). IFN-γ levels were lower than 100 pg\ml in glucan-treated mice at all time points measured. Therefore glucan alone did not induce significant secretion of IFN-γ into serum. However, glucan treatment potentiated LPS-induced serum IFN-γ levels and splenic IFN-γ mRNA expression. In control mice, splenic IFN-γ mRNA expression peaked at 3 h after LPS challenge ( Figure 1B ). Glucan-primed mice exhibited prolonged IFN-γ mRNA expression compared with saline-primed mice. Specifically, glucan- Blood was harvested after 0, 1, 2, 6 and 12 h, and IFN-γ levels in serum were determined by ELISA. *Significantly (P 0.05) greater than in glucan-treated mice.
(B) Time course of LPS-induced splenic IFN-γ mRNA expression. Mouse spleens were harvested at the indicated time points after LPS challenge (4 mg/kg), total RNA was isolated and IFN-γ mRNA expression was measured by RT-PCR. (C) Splenic IFN-γ expression after LPS challenge. Control and LPS-tolerant mice treated or not with glucan were challenged with LPS, spleens were harvested after 3 h and IFN-γ mRNA expression was measured by RPA. (D) Serum IFN-γ levels at 3 and 6 h after LPS challenge. Sera were harvested from mice at 3 and 6 h after LPS challenge and IFN-γ levels were determined by ELISA. k, Non-glucan-treated mice ; j, glucantreated mice (n l 4-6 mice/group). *Significantly (P 0.05) greater than in non-glucan-treated mice.
primed mice exhibited detectable IFN-γ mRNA expression at 6 h after LPS challenge. IFN-γ mRNA expression was not detectable in the spleens of control mice at this time point within the limits of our assay. LPS-tolerant mice did not exhibit detectable splenic IFN-γ mRNA expression at any of the time points studied. However, LPS-tolerant mice treated with glucan showed splenic IFN-γ expression at 3 h after LPS challenge. The effect of glucan treatment on splenic IFN-γ mRNA expression was also determined using an RPA ( Figure 1C) . At 3 h after LPS challenge, saline-and glucan-primed control mice exhibited similar levels of IFN-γ mRNA expression. However, LPS-induced IFN-γ expression was markedly decreased in the spleens of LPS-tolerant mice. Splenocytes from mice that had received glucan during the induction of LPS tolerance exhibited IFN-γ expression that was similar to that in control mice. Glucan treatment also potentiated LPS-induced secretion of IFN-γ into serum and attenuated the suppression of IFN-γ production associated with LPS tolerance ( Figure 1D ). In control mice, glucan treatment caused a greater than 2-fold increase in LPS-induced IFN-γ levels in serum compared with those in salinetreated control mice at 3 h after LPS challenge, and a greater than 1-fold increase at 6 h. In LPS-tolerant mice, there was negligible secretion of IFN-γ following LPS challenge. However, co-administration of glucan during the induction of LPS tolerance resulted in a greater than 10-fold increase in IFN-γ secretion into serum at 3 and 6 h after LPS challenge compared with saline-treated LPS-tolerant mice. Glucan phosphate potentiates interferon-γ expression Splenocytes were harvested from mice and cultured (1i10 6 cells/well) in 96-well plates with LPS (100 ng/ml) for 24 h, and conditioned media were harvested for measurement of IFN-γ using ELISA (n l 8-12 wells/group). In some groups, antibodies against IL-12 (1 µg/ml) and/or IL-18 (10 µg/ml) were added prior to challenge. Non-specific goat IgG (10 µg/ml) served as a control. *Significantly (P 0.05) less than with goat IgG.
Glucan treatment attenuates the suppression of IL-12 production observed in LPS-tolerant mice
The functional roles of IL-12 and IL-18 in the LPSinduced production of IFN-γ were determined in studies using blocking antibodies to each cytokine ( Figure 2 ). As controls, cultured splenocytes were incubated without antibodies or with non-specific goat IgG prior to LPS challenge. Addition of antibodies specific for IL-12 inhibited LPS-induced IFN-γ production by 86 %, while anti-IL-18 antibodies decreased IFN-γ secretion by 31 % compared with controls. The use of both antibodies did not decrease LPS-induced IFN-γ secretion more than did anti-IL-12 antibodies alone.
Studies were undertaken to determine the effects of glucan treatment on the production of IL-12 after LPS challenge. IL-12 p40 mRNA was expressed in the spleens of both saline-treated and glucan-treated control mice, and peaked at 1 h after LPS challenge, as determined by RT-PCR ( Figure 3A) . IL-12 p40 mRNA was not detectable in the spleens of LPS-tolerant mice at any of the time points studied within the limits of our assay. However, co-administration of glucan with LPS during the induction of LPS tolerance attenuated the suppression of IL-12 p40 mRNA expression ( Figure 3A) . Splenic IL-12 mRNA expression was also examined by RPA ( Figure  3B ). Spleens from mice in all groups expressed similar levels of IL-12 p35. However, in the control group, IL-12 p40 mRNA expression was increased in glucan-treated mice compared with saline-treated mice. IL-12 p40 mRNA expression was suppressed in LPS-tolerant mice, but glucan treatment attenuated the decrease in IL-12 p40 expression in the LPS-tolerant group.
In control mice, glucan treatment did not potentiate IL-12 secretion into serum compared with that in salinetreated controls at 3 or 6 h after LPS challenge ( Figure  3C ). In both groups, serum IL-12 levels peaked at 3 h after LPS administration. Induction of LPS tolerance resulted in suppression of serum IL-12 levels to less than 5 % of control values. Glucan treatment partially prevented the suppression of LPS-induced IL-12 secretion in the LPS-tolerant group. Specifically, IL-12 levels were 17-and 27-fold greater in glucan-treated mice compared with those in non-glucan-treated, LPS-tolerant mice at 3 and 6 h respectively after LPS challenge.
Glucan treatment increases IL-18 levels in serum, but not in the spleen
Splenic IL-18 mRNA expression in control and LPStolerant mice was examined by RPA ( Figure 4A ). IL-18 mRNA was constitutively expressed in the spleens of control and LPS-tolerant mice. IL-18 mRNA levels were not significantly different between groups prior to LPS challenge. LPS challenge increased IL-18 mRNA expression in control mice, but not in LPS-tolerant mice. However, glucan-treated LPS-tolerant mice exhibited increased IL-18 mRNA expression compared with nonglucan-treated LPS-tolerant mice. IL-18 protein levels in sera were also ascertained in control and LPS-tolerant mice. Consistent with mRNA levels, all groups exhibited constitutive levels of IL-18 in serum prior to LPS challenge, and the levels did not differ significantly between groups ( Figure 4B ). LPS induced a significant increase in serum IL-18 in both control and LPS-tolerant mice treated with glucan, but not in non-glucan-treated mice.
Additional studies were undertaken to define IL-18 processing in the spleens of control and LPS-tolerant mice. We observed constitutive expression of 25 kDa pro-IL-18 in the spleens of mice from all groups ( Figure  4C ). The 18 kDa mature form of IL-18 was not observed in whole-spleen homogenates. Little change in pro-IL-18 levels was observed in spleens after LPS challenge, and no significant differences in pro-IL-18 expression were observed between control and LPS-tolerant mice. Glucan treatment did not alter pro-IL-18 levels in the spleens of mice. We also measured IL-1-converting enzyme (ICE), which cleaves pro-IL-18 (25 kDa) into the mature form of IL-18 (18 kDa), in cultured splenocytes ( Figure 4D ). Splenocytes harvested from control and LPS-tolerant mice were cultured with or without LPS (100 ng\ml) for 4 h, and ICE expression was determined by Western blotting with antibodies against ICE p20. ICE was constitutively expressed in all groups. Immunoreactive bands consistent with the 45 kDa ICE precursor and the 20 kDa p20 component of ICE were observed. Culture (A) Control and LPS-tolerant mice were challenged with LPS (4 mg/kg). Spleens and sera were harvested for analysis at the indicated time points. Splenic IL-12 p40 mRNA expression was determined by RT-PCR. (B) Spleens were harvested from mice 1 h after LPS challenge. IL-12 p35 and IL-12 p40 mRNA expression was determined by RPA. (C) Mouse sera were harvested at 3 and 6 h after LPS challenge. IL-12 content was determined by ELISA. k, Non-glucan-treated mice ; j, glucan-treated mice (n l 4-6 mice/group). *Significantly (P 0.05) greater than in non-glucan-treated controls.
Figure 4 Glucan phosphate potentiates endotoxin (LPS)-induced IL-18 production
(A) Spleens were harvested from mice either before or 1 h after intraperitoneal LPS challenge (4 mg/kg). IL-18 mRNA expression was measured by RPA. (B) Sera were harvested at 0 and 3 h after LPS challenge. IL-18 levels were determined by ELISA (n l 4-6 mice/group). *Significantly (P 0.05) greater than in non-glucantreated controls. (C) Spleens were harvested from control and LPS-tolerant mice at the time points indicated after LPS challenge. Total protein was harvested and Western blotting was performed using polyclonal anti-IL-18 antibodies. (D) Splenic pan-leucocytes were harvested and cultured with or without LPS for 4 h. Western blotting using polyclonal antibodies against ICE p20 was performed on cell lysates. Immunoreactive bands typical of pro-ICE (p45) and ICE p20 are shown. k, Non-glucantreated mice ; j, glucan-treated mice. Glucan phosphate potentiates interferon-γ expression
Figure 5 Glucan increases IFN-γ secretion by splenic T cells and NK cells in response to exogenous IL-12 and IL-18
(A) T cells were isolated from the spleens of control and LPS-tolerant mice and incubated with IL-18 at the concentrations shown for 72 h, and conditioned media were harvested to determine IFN-γ content by ELISA (n l 8-12 wells/group). (B) Splenic T cells and NK cells were isolated as above. Cells were incubated with IL-12 (1 ng/ml) and IL-18 (10 ng/ml) for 24 h, and conditioned media were harvested to determine IFN-γ levels by ELISA (n l 6-10 wells/group). k, Nonglucan-treated mice ; j, glucan-treated mice. *Significantly (P 0.05) greater than in non-glucan-treated controls.
of splenocytes with LPS did not change ICE expression in any of the experimental groups.
T cell/NK cell responsiveness to IL-12 and IL-18 is enhanced in glucan-treated mice
Splenic T cells and NK cells were isolated from both control and LPS-tolerant mice treated or not with glucan, and IFN-γ secretion in response to added IL-12 and IL-18 was assessed ( Figure 5 ). Splenic T and NK cells isolated from either control or LPS-tolerant mice treated with glucan exhibited a greater than 10-fold increase in IFN-γ secretion in response to 100 ng\ml IL-18 compared with T cells obtained from corresponding salinetreated mice ( Figure 5A ). IL-12 alone did not induce IFN-γ secretion by isolated T or NK cells (results not shown). However, T and NK cells isolated from glucantreated mice exhibited approx. 1-fold and 1.5-fold increases in IFN-γ secretion in response to IL-12 and IL-18 compared with saline-treated controls in both the control and LPS-tolerant groups respectively ( Figure  5B) .
Because of the increased responsiveness of T and NK cells from glucan-treated mice to IL-12 and IL-18, we assessed the expression of IL-12 and IL-18 receptor mRNAs in the spleens of control and glucan-treated mice ( Figure 6 ). We also evaluated the expression of IFN-γ receptor (IFN-γR) mRNA. The IFN-γRα and IFN-γRβ subunit mRNAs were strongly expressed at similar levels in all groups ( Figure 6A ). IL-12 receptor β " (IL-12Rβ " ) subunit mRNA was also expressed at similar levels in all groups ( Figure 6B ). IL-12Rβ # mRNA levels were increased in glucan-treated control mice compared with saline-treated controls. Induction of LPS tolerance resulted in suppressed IL-12Rβ # mRNA expression that was not changed significantly by glucan treatment. Assessment of splenic IL-18Rα mRNA expression using RT-PCR showed greater receptor expression in glucantreated mice compared with non-glucan-treated mice ( Figure 6C ). The highest levels of IL-18Rα mRNA expression were observed in glucan-treated, LPS-tolerant mice.
DISCUSSION
The present study shows that glucan phosphate treatment potentiates the LPS-induced production of IFN-γ in control mice. The increase in LPS-induced IFN-γ production is correlated with increased expression of the IFN-γ-inducing cytokines IL-12 and IL-18. Additionally, cultured splenocytes from glucan-treated mice are more responsive to exogenous IL-12 and IL-18, which correlates with the elevated expression of IL-12Rβ # and IL-18Rα in the spleens of mice receiving glucan treatment. Previous studies have demonstrated that glucan therapy enhances macrophage-mediated antimicrobial functions such as phagocytosis and respiratory burst activity, with associated resistance to a broad range of infections [9, 10] . However, the mechanisms behind the glucan-induced potentiation of macrophage function have not been well delineated. Our studies show that glucan phosphate primes the immune system to produce increased levels of IFN-γ in response to an inflammatory stimulus. IFN-γ is a major endogenous activator of macrophage function that is produced primarily by activated T cells and NK cells [17, 18] . One of the major actions of IFN-γ is to amplify macrophage functions such as phagocytosis, respiratory burst activity, antigen presentation and cytokine secretion [19, 20] . Therefore the results of our studies suggest a correlation between the ability of glucan to potentiate IFN-γ expression and increased antimicrobial immunity. Further studies using IFN-γ −/− or IFN-γR −/− transgenic mice will need to be performed in order to establish fully a cause-and-effect relationship between increased IFN-γ expression and enhanced resistance to infection in glucan-treated mice.
We also defined the effect of glucan treatment on IL-12 and IL-18 expression and function. IL-12 and IL-18 are known to act synergistically to induce IFN-γ expression [18] . Our study shows that IL-12 and IL-18 play functional roles in LPS-induced IFN-γ production, and that glucan treatment potentiates the LPS-induced expression of splenic IL-12 p40 mRNA in control and LPStolerant mice, and of IL-12Rβ # mRNA in the spleens of control mice. Serum IL-18 levels and expression of the IL-18Rα subunit in mouse spleen were also increased in glucan-treated mice. The increases in IL-12Rβ # and IL-18Rα expression correlate with the increased responsiveness of T cells to exogenous IL-12 and IL-18. These findings indicate alterations in both macrophage and T cell function after glucan treatment. IL-12 and IL-18 are produced primarily by macrophages, dendritic cells and other antigen-presenting cells [21, 22] . However, IFN-γ is secreted mainly by activated T cells and NK cells [17, 18] . Therefore glucan appears to prime macrophages to increase cytokine secretion, and T\NK cells to enhance their responsiveness to IFN-γ-inducing stimuli.
Co-administration of glucan with LPS during induction of LPS tolerance attenuated the LPS-induced suppression of IFN-γ and IL-12 in tolerant mice. Prior studies have shown that IFN-γ secretion is impaired in experimental models of trauma, thermal injury and LPS tolerance [3, 23, 24] . Our results confirm the observation that IFN-γ production is suppressed at the transcriptional level in LPS-tolerant mice, with a concomitant decrease in serum IFN-γ content [3] . The model of LPS tolerance has clinical significance, because it mimics many of the alterations in immune function seen after major trauma, thermal injury or sepsis [3, 8, 23, 25] . Infectious complications are a major source of morbidity and mortality in this patient population. Decreased production of IFN-γ has been postulated to be a major factor in the increased susceptibility of critically injured patients to infectious complications. Administration of IFN-γ has been shown to improve immune function, and, in some cases, to decrease infections in high-risk surgical and trauma patients [1, 4, 5, 26] . The present study demonstrates the ability of glucan phosphate to sustain LPS-induced IFN-γ production in LPS-tolerant mice, indicating that glucan may be beneficial as an immunomodulator in critically injured patients or those with sepsis.
Suppression of IL-12 expression following trauma or induction of LPS tolerance has been demonstrated previously [3, 23] . In experimental trauma models, IL-12 therapy has been shown to enhance resistance to infection, an effect that is mediated, in part, by stimulation of IFN-γ secretion [8] . Administration of IL-12 has been shown to be more effective than IFN-γ in enhancing antimicrobial immunity in some experimental models [8] . This is likely to be due to immunological functions of IL-12 that go beyond its ability to stimulate IFN-γ secretion. These functions include promotion of type I T cell differentiation, enhancement of NK cell activity, and autocrine activation of macrophage function [18, 27, 28] . The present study shows that IL-12 expression is suppressed primarily at the transcriptional level in the spleens of LPS-tolerant mice. This finding confirms prior studies by Karp and colleagues [29] that demonstrated transcriptional suppression of IL-12 p40 expression in cultured macrophages and dendritic cells that were rendered LPS tolerant in vitro. Our study also shows that glucan phosphate treatment attenuates the suppression of IL-12 p40 gene transcription and IL-12 p70 protein secretion observed in LPS-tolerant mice.
The molecular mechanisms by which glucans antagonize the induction of LPS tolerance are not known. Studies by Williams and colleagues [30] have shown that glucan treatment attenuates the pro-inflammatory response induced by intra-abdominal sepsis in rats. This effect is associated with inhibition of the sepsis-induced nuclear translocation of nuclear factor-κB (NF-κB) in the glucan-treated mice. Paradoxically, glucan phosphate itself has been shown to stimulate the nuclear translocation of NF-κB, although to a lesser degree than LPS [31] . Furthermore, induction of NF-κB translocation by soluble glucans is not associated with transactivation of pro-inflammatory cytokine genes [32] . The induction of LPS tolerance requires prior LPS-induced activation of NF-κB [33] . Based on these findings, one could speculate that glucan-induced signalling pathways compete with pathways involved in NF-κB activation by LPS, resulting in decreased pro-inflammatory cytokine gene transcription. This initial antagonism of LPS-induced translocation by glucan may attenuate the LPS-tolerant response.
We observed constitutive expression of IL-18 mRNA in the spleen and the presence of IL-18 protein in serum prior to LPS challenge. ICE was also constitutively expressed in the spleens of control and LPS-tolerant mice. Significant differences in ICE expression were not observed among groups. Glucan treatment potentiated the LPS-induced secretion of IL-18 into serum. Previously, little was known about the effect of LPS tolerance on IL-18 production. Unlike IL-12 and IFN-γ, we did not observe significant suppression of IL-18 expression in LPS-tolerant mice. This may be important, because recent studies have shown that IL-18, in the absence of IL-12, will promote the differentiation of T cells into the type 2 (or Th2) phenotype [34, 35] . The predominance of Th2 cells has been shown to occur in severely injured patients and to correlate with increased infectious complications [36, 37] . Our observation that IL-18 expression, unlike that of IL-12, is not suppressed 2 days after the induction of endotoxin tolerance provides one potential mechanism for the induction of the Th2 phenotype following trauma or sepsis.
The biological effects of IL-18 are mediated through cell surface IL-18Rs. The IL-18R complex is composed of two subunits, termed IL-18Rα and IL-18Rβ. The IL-18Rα subunit, known previously as IL-1-receptor-related protein (IL-1Rrp), is thought to be the primary ligand-binding component of the receptor [38] [39] [40] . IL-18Rβ was initially termed accessory protein-like (AcPL) because of its accessory function in IL-18R signalling [41] . Studies indicate that both subunits are required to mediate IL-18-induced functions. There is evidence that IL-18Rβ, but not IL-18Rα, is constitutively expressed on T cells [41, 42] . Our results support the notion that IL-18Rα is not constitutively expressed on splenocytes. Our study also showed that glucan is a potent inducer of IL-18Rα expression. The increase in IL-18Rα expression was correlated with increased splenic T cell responsiveness to IL-18, either alone or in combination with IL-12. The ability of glucan phosphate to up-regulate IL-18Rα expression may provide a novel mechanism for the treatment of injury-induced immunosuppression.
Overall, the present study demonstrates the ability of glucan to enhance LPS-induced IFN-γ production in control mice, and to attenuate the induction of LPS tolerance. Elevated IL-12 and IL-18 production and increased expression of IL-12Rs and IL-18Rs were observed in glucan-treated mice. Numerous studies have demonstrated the ability of glucan to enhance host resistance to a variety of experimental infections [9, 10] . Clinical studies have shown the ability of glucans to enhance immune function and decrease infectious complications in high-risk surgical patients and those suffering from severe trauma [11] [12] [13] [14] . The ability of glucans to augment the production of cytokines that play an important role in antimicrobial immunity denotes its potential benefit in the setting of trauma and sepsis. These studies also define a workable mechanism of glucan-enhanced antimicrobial immunity.
